The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
REGULATORY
Takecab Faces 15.8% Slash, GLP-1s 11.1% in FY2022 Drug Price Revision
Japan’s health ministry on March 4 announced new NHI prices for listed medicines, effective April 1, revealing a 15.8% slash for Takeda Pharmaceutical’s acid reducer Takecab (vonoprazan), and up to 11.1% for injectable GLP-1 agents. The Ministry of Health, Labor…
To read the full story
Related Article
REGULATORY
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
- Regulatory Reform Panel Calls for Review of Clinical Trial Ad Rules
May 30, 2025
- Ishin Nixes Ruling Bloc’s Draft Social Security Plans over OTC-Like Drug Issue
May 30, 2025
- LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
May 29, 2025
- LDP Fiscal Reform HQ’s Proposal Keeps Budget Ceiling Intact, but Urges Action on Wage Front
May 28, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…